Search Within

Gregory J Riely

Formats
  1. Journal Article (295)
  2. Meeting Abstract (265)
  3. Book Section (16)
  4. Guidelines (15)
  5. Conference Paper (4)
  6. Review (4)
  7. Editorial (3)
  8. Book Whole (1)
  9. Correspondence (1)
  10. Research Letter (1)
Groups
  1. Department of Medicine (605)
  2. Solid Tumor Oncology Division (605)
  3. Thoracic Oncology (605)
  4. Department of Pathology and Laboratory Medicine (262)
  5. GSK Faculty (248)
  6. Human Oncology and Pathogenesis Program (223)

More Groups

People
  1. Mark Kris (222)
  2. Marc Ladanyi (188)
  3. Helena Yu (108)
  4. Maria Arcila (85)
  5. Vincent Miller (79)
  6. Charles Rudin (76)

More People

Years
  1. 2025 (9)
  2. 2024 (25)
  3. 2023 (45)
  4. 2022 (39)
  5. 2021 (41)
  6. 2020 (29)

More Years

Publications
  1. Journal of Clinical Oncology (157)
  2. Journal of Thoracic Oncology (113)
  3. Clinical Cancer Research (46)
  4. Annals of Oncology (32)
  5. Journal of the National Comprehensive Cancer Network (26)
  6. Cancer Research (14)

More Publications

Publishers
  1. American Society of Clinical Oncology (175)
  2. Elsevier Inc. (137)
  3. American Association for Cancer Research (77)
  4. Oxford University Press (39)
  5. Harborside Press (26)
  6. Elsevier Science, Inc. (23)

More Publishers

Results (605)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase 3 study of pemetrexed-platinum with or without pembrolizumab for TKI-resistant/EGFR-mutated advanced NSCLC: KEYNOTE-789
    Meeting Abstract

    Riely, G.; Hui, R.; Carbone, D.; Park, K.; Carrigan, M.; Xu, X.; Dang, T.; Yang, J. C. H.
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 in NSCLC
    Meeting Abstract

    Neal, J.; Doebele, R.; Riely, G.; Spira, A.; Horn, L.; Piotrowska, Z.; Costa, D.; Zhang, S.; Bottino, D.; Zhu, J.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • MET exon 14-altered lung cancers: Central nervous system (CNS) metastases and patterns of CNS progression on MET inhibition
    Meeting Abstract

    Offin, M.; Dienstag, J.; Wilkins, O.; Sabari, J.; Ni, A.; Feldman, D.; Van Voorthuysen, M.; Suzawa, K.; Yu, H.; Riely, G.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Utility of cfDNA testing for acquired resistance: The Memorial Sloan Kettering experience with plasma EGFR T790M clinical testing
    Meeting Abstract

    Offin, M.; Myers, M.; Josyula, S.; Shen, R.; Borsu, L.; Tsui, D.; Riely, G.; Rudin, C.; Yu, H.; Li, B.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Concurrent mutations in STK11 and KEAP1 is associated with resistance to PD-(L)1 blockade in patients with NSCLC despite high TMB
    Meeting Abstract

    Arbour, K.; Shen, R.; Plodkowski, A.; Rizvi, H.; Ni, A.; Long, N.; Halpenny, D.; Sanchez-Vega, F.; Rudin, C.; Riely, G.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Updated antitumor activity of crizotinib in patients with MET exon 14-altered advanced non-small cell lung cancer
    Meeting Abstract

    Drilon, A.; Clark, J.; Weiss, J.; Ou, S.; Camidge, D. R.; Solomon, B.; Otterson, G.; Villaruz, L.; Riely, G.; Heist, R.; more...
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Clinical activity of lorlatinib in patients with ROS1+ advanced non-small cell lung cancer: Phase 2 study cohort EXP-6
    Meeting Abstract

    Ou, S.; Shaw, A.; Riely, G.; Chiari, R.; Bauman, J.; Clancy, J.; Thurm, H.; Peltz, G.; Abbattista, A.; Solomon, B.
    Journal of Thoracic Oncology (2018)

    Fulltext@MSK | Save
  • Lorlatinib in patients with ALK-positive non-small-cell lung cancer: Results from a global phase 2 study
    Journal Article

    Solomon, B. J.; Besse, B.; Bauer, T. M.; Felip, E.; Soo, R. A.; Camidge, D. R.; Chiari, R.; Bearz, A.; Lin, C. C.; Gadgeel, S. M.; more...
    Lancet Oncology (2018)

    Fulltext@MSK | Save
  • PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers
    Journal Article

    Sabari, J. K.; Leonardi, G. C.; Shu, C. A.; Umeton, R.; Montecalvo, J.; Ni, A.; Chen, R.; Dienstag, J.; Mrad, C.; Bergagnini, I.; more...
    Annals of Oncology (2018)

    Fulltext@MSK | Save
  • Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: Results from a phase II basket trial
    Journal Article

    Li, B. T.; Shen, R. L.; Buonocore, D.; Olah, Z. T.; Ni, A.; Ginsberg, M. S.; Ulaner, G. A.; Offin, M.; Feldman, D.; Hembrough, T.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save